Skip to content
  • Kategorier
  • Seneste
  • Etiketter
  • Populære
  • Verden
  • Bruger
  • Grupper
Temaer
  • Light
  • Brite
  • Cerulean
  • Cosmo
  • Flatly
  • Journal
  • Litera
  • Lumen
  • Lux
  • Materia
  • Minty
  • Morph
  • Pulse
  • Sandstone
  • Simplex
  • Sketchy
  • Spacelab
  • United
  • Yeti
  • Zephyr
  • Dark
  • Cyborg
  • Darkly
  • Quartz
  • Slate
  • Solar
  • Superhero
  • Vapor

  • Default (No Skin)
  • No Skin
Kollaps
  1. Debatforum
  2. Kategorier
  3. Genmab
  4. Genmab — November 2023

Genmab — November 2023

Planlagt Fastgjort Låst Flyttet Genmab
1.5k Indlæg 1 Posters 0 Visninger
  • Ældste til nyeste
  • Nyeste til ældste
  • Most Votes
Svar
  • Svar som emne
Login for at svare
Denne tråd er blevet slettet. Kun brugere med emne behandlings privilegier kan se den.
  • StockBullS Offline
    StockBullS Offline
    StockBull
    wrote on sidst redigeret af
    #1419

    Så de ligger sig bare op ad ca. samme target omkring 2400 som mange af de andre også har nedjusteret til.

    1 Reply Last reply
    0
    • E Offline
      E Offline
      E_L
      wrote on sidst redigeret af
      #1420

      patient report- Cycle 4, Epcoritamab Trial for CLL / SLL https://cllsociety.org/2023/11/cycle-4-epcoritamab-trial-for-cll-sll/

      1 Reply Last reply
      0
      • T Offline
        T Offline
        Teller
        wrote on sidst redigeret af
        #1421

        Hvis renten forbliver mellem 3,5 - 5 % frem til patentudløb, og på den baggrund af nuværende pipeline status, er kurs 2000 - 2400 kr vel ikke helt ved siden af.

        1 Reply Last reply
        0
        • StockBullS Offline
          StockBullS Offline
          StockBull
          wrote on sidst redigeret af
          #1422

          Renten bliver normalt sænket meget hvis der er recession. En recession er jo tegn på økonomien går ad H til. Typisk vil en recession være årsagen til, at obligationskurserne stiger – og renterne falder meget – da det får centralbanken til at sænke renten og stimulere økonomien, mens investorerne søger sikker havn i statsobligationerne.

          1 Reply Last reply
          0
          • B Offline
            B Offline
            bibob
            wrote on sidst redigeret af
            #1423

            Børsen kl 10. Genmab partner falder 17 % efter fejlet forsøg.

            1 Reply Last reply
            0
            • E Offline
              E Offline
              E_L
              wrote on sidst redigeret af
              #1424

              yea... another day another biotech getting slammed...

              1 Reply Last reply
              0
              • T Offline
                T Offline
                Teller
                wrote on sidst redigeret af
                #1425

                Har Genmab overhovedet del i deres fejlede bløder medicin?

                1 Reply Last reply
                0
                • E Offline
                  E Offline
                  E_L
                  wrote on sidst redigeret af
                  #1426

                  no, not at all

                  1 Reply Last reply
                  0
                  • E Offline
                    E Offline
                    E_L
                    wrote on sidst redigeret af
                    #1427

                    Novartis approximates Kesimpta Peak sales at $4bn in their investor presentation https://www.novartis.com/sites/novartiscom/files/novartis-investors-r-d-day-2023.pdf

                    1 Reply Last reply
                    0
                    • E Offline
                      E Offline
                      E_L
                      wrote on sidst redigeret af
                      #1428

                      Genmab A/S (NASDAQ:GMAB) Stock Rating Reaffirmed by HC Wainwright -"buy" rating restated by stock analysts at HC Wainwright in a report issued on Tuesday, Benzinga reports. They presently have a $49.00 target price

                      1 Reply Last reply
                      0
                      • K Offline
                        K Offline
                        Klarussen
                        wrote on sidst redigeret af
                        #1429

                        Hvis den gik 3% ned i går på en "hold" anbefaling, så burde det her da kunne løfte den med et kursmål sv.t. 3332 kr.

                        1 Reply Last reply
                        0
                        • W Offline
                          W Offline
                          w
                          wrote on sidst redigeret af
                          #1430

                          Når der først er gået sur røv i en aktie, så
                          ser det svært ud

                          1 Reply Last reply
                          0
                          • L Offline
                            L Offline
                            lahn1
                            wrote on sidst redigeret af
                            #1431

                            Tror ikke fib 61,8 holder her. Tror vi skal have lukket det gap i 2035 imorgen. Så er vi også klar til ny op-tur frem mod ASH.

                            1 Reply Last reply
                            0
                            • E Offline
                              E Offline
                              E_L
                              wrote on sidst redigeret af
                              #1432

                              3rd attempt for the German 10y bund yield to break below the 2.50% level this month; hopefully that can give us a bit of headwind...

                              1 Reply Last reply
                              0
                              • SolsenS Offline
                                SolsenS Offline
                                Solsen
                                wrote on sidst redigeret af
                                #1433

                                Tak EL (11:30) - Kesimpta fylder efterhånden en del i værdiansættelsen af Genmab.

                                1 Reply Last reply
                                0
                                • E Offline
                                  E Offline
                                  E_L
                                  wrote on sidst redigeret af
                                  #1434

                                  FDA Investigating Serious Risk of T-cell Malignancy Following BCMA-Directed or CD19-Directed Autologous Chimeric Antigen Receptor (CAR) T cell Immunotherapies https://www.fda.gov/vaccines-blood-biologics/safety-availability-biologics/fda-investigating-serious-risk-t-cell-malignancy-following-bcma-directed-or-cd19-directed-autologous

                                  1 Reply Last reply
                                  0
                                  • K Offline
                                    K Offline
                                    Klarussen
                                    wrote on sidst redigeret af
                                    #1435

                                    E L: can you enlighten us novices to the importance of this information in regard to Genmab?

                                    1 Reply Last reply
                                    0
                                    • K Offline
                                      K Offline
                                      Klarussen
                                      wrote on sidst redigeret af
                                      #1436

                                      @w 15:50: spot on, gælder iøvrigt for mange andre fohold i livet end aktier

                                      1 Reply Last reply
                                      0
                                      • SolsenS Offline
                                        SolsenS Offline
                                        Solsen
                                        wrote on sidst redigeret af
                                        #1437

                                        https://firstwordpharma.com/story/5804477?from=article For Genmab er det Carvykti der er interessant. Er af JNJ slået op til noget stort i myeloma - dara konkurrent. Så dette er meget vigtig for Genmab.

                                        1 Reply Last reply
                                        0
                                        • K Offline
                                          K Offline
                                          Klarussen
                                          wrote on sidst redigeret af
                                          #1438

                                          Tak Solsen

                                          1 Reply Last reply
                                          0

                                          Hello! It looks like you're interested in this conversation, but you don't have an account yet.

                                          Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.

                                          With your input, this post could be even better 💗

                                          Tilmeld Log ind
                                          Svar
                                          • Svar som emne
                                          Login for at svare
                                          • Ældste til nyeste
                                          • Nyeste til ældste
                                          • Most Votes


                                          • Log ind

                                          • Har du ikke en konto? Tilmeld

                                          • Login or register to search.
                                          Powered by NodeBB Contributors
                                          • First post
                                            Last post
                                          0
                                          • Kategorier
                                          • Seneste
                                          • Etiketter
                                          • Populære
                                          • Verden
                                          • Bruger
                                          • Grupper